Organon (OGN) Proxy filing summary

Executive summary

• Entered into a Merger Agreement with Sun Pharmaceutical Holdings USA, Inc., with the company to become a wholly owned subsidiary of Sun Pharma USA following the merger.

• Special meeting of stockholders scheduled for July 23, 2026, to vote on the proposed merger.

• Supplemental disclosures provided in response to litigation alleging incomplete and misleading proxy statement information.

• Forward-looking statements highlight risks related to transaction timing, regulatory approvals, competing offers, and potential impacts on business operations.

Voting matters and shareholder proposals

• Stockholders are to vote on the merger proposal at the special meeting.

• Litigation seeks to enjoin the stockholder vote pending additional disclosures; company voluntarily supplemented proxy statement to address concerns.

Board of directors and corporate governance

• Board evaluated multiple strategic alternatives, including Sun Pharma's proposal and other potential transactions.

• Board determined not to pursue a transaction at $13.50 per share and considered execution risks of alternative strategies.